Hereditary non-polyposis colorectal cancer (HNPCC) is a syndrome of inherited bowel and other cancers that has been said to account for up to 15% of all colorectal carcinomas (CRCs). HNPCC can now be diagnosed at the molecular level by detecting germline mutations in genes involved in mismatch repair. A current problem is to determine the prevalence of HNPCC mutations in colon cancer patients with limited or no family history, especially in cases of early onset. We have identified 50 cases of non-polyposis colorectal cancer without a family history of CRC or any other HNPCC cancer, who presented under the age of45 years. Germline HNPCC variants (at the hMSH2 or hMLHl loci) were detected in a small minority of cases (6%). The variants that we have found may be new or low penetrance mutations, or even polymorphisms. It remains possible that some of our sample have an inherited predisposition to CRC that is not caused by HNPCC mutations or by known polyposis syndromes. Our data suggest that most HNPCC mutations occur in families and have high or moderate penetrance. New or low penetrance HNPCC mutations probably do not contribute significantly to the risk ofcolorectal cancer in the general population and probably account for much fewer than 15% of ali CRCs. Our results question whether mass population genetic screening programmes are worthwhile for diseases such as HNPCC using current technology.
Hereditary non-polyposis colorectal cancer (HNPCC) is a syndrome of inherited bowel cancer that accounts in some studies for 5 to 15% of all colorectal carcinomas (CRCs).'
Colon cancers in HNPCC families tend to be right sided, early onset, mucinous, multiple, and ofgood stage for stage prognosis. Clinically, HNPCC has been defined according to the "Amsterdam criteria": (1) three or more relatives affected by CRC, one a first degree relative of the other two; (2) two or more generations affected; (3) one or more CRCs presenting before 50 years of age; and (4) exclusion of hereditary polyposis syndromes.
These criteria have been criticised on two grounds. First, they do not include the extracolonic tumours that tend to occur in HNPCC families, particularly cancers of the uterus, ovary, kidney, stomach, skin, and urinary epithelium. Second, the "Amsterdam criteria" may wrongly exclude patients with a more limited family history (owing to factors such as new mutations, reduced penetrance, death before cancer is diagnosed, and incomplete history taking or diagnosis).
Most families with HNPCC are caused by germline mutations in one of four genes (hMSH2, hMLHl, hPMS1, hPMS2) that are involved in DNA mismatch repair.2`As an alternative to the "Amsterdam criteria", it iS now possible to define HNPCC by the presence of a functional germline mutation at an HNPCC locus. Two problems of immediate importance are to determine the prevalence of HNPCC mutations (1) in colon cancer families with relatively late age ofonset and (2) in people with colon cancer but without significant family history. In the latter case, whether or not patients with apparently sporadic colon cancer actually have germline HNPCC mutations greatly influences their own risk of metachronous colon cancer and extracolonic cancers, and affects their relatives' risk of cancer. Germline HNPCC mutations are likely to be most frequent in non-familial CRCs which present at an early age, owing either to new mutations or to low penetrance HNPCC alleles, which might contribute to the risk of cancer in all age groups. If, however, germline HNPCC mutations are rare in young colon cancer patients, it suggests that most HNPCC mutations have high penetrance, that most HNPCC occurs within families, and that HNPCC is responsible for fewer CRCs than the 15% suggested by some studies.
From medical records, we have identified 50 cases ofcolorectal cancer without family history that presented at <45 years of age (median 39, range 15-45) (table 1). The risk of CRC to the first degree relatives of patients with CRC at <45 years is about 1 in 10,6 compared with a population risk of about 1 in 35, but these data are not strictly comparable with our study. No patient was included in our study if 17 which went undetected. Two factors may cause our estimate of 6% to be too high. First, imperfect reporting or recording offamily histories may have led some truly familial cases of HNPCC to be included in our sample. Since most patients were ascertained through surgeons with a special interest in colorectal cancer, from dedicated colorectal units, or through cancer genetics clinics, we believe that inaccuracy from this source is probably low. Second, HNPCC may have a better prognosis than other types of colorectal cancer'8; although not all our patients were alive at the time of this study, it is possible that early death of other cases caused HNPCC to be over-represented in our sample. Taking all factors into account, we suggest that fewer than 10% of CRC cases under 45 years of age have germline HNPCC mutations.
A previous study" analysed 31 cases of CRC who presented before 35 years of age and did not have a family history fulfilling the "Amsterdam criteria". Of these cases, 58% of the patients' tumours had microsatellite instability; this is found in about 90% of HNPCC cancers and 10 to 20% of sporadic CRCs, but many cancers have microsatellite instability without detectable germline or somatic HNPCC mutations. Twelve patients were analysed for germline mutations at hMSH2, hMLH1, hPMS1, and hPMS2, and, of these, five (42%) had truncating mutations at hMSH2 or hMLH1; no other germline mutations were detected. In contrast, none of our 12 patients under 35 years old had mutations at hMSH2 or hMLH1 (although one case was 37 years old). Liu et all' did not study the frequency of germline HNPCC mutations in patients over 35 years of age, although microsatellite instability occurred in only 17% of the tumours from their patients in the 35 to 55 age group. The differences between our results and those of Liu et all" probably arise from the more stringent selection against family history that was used in our study. In addition, the age ranges studied may have led to even greater selection against family history in our sample than in that of Liu et 45 years old cannot be directly extended to the general population; it is likely, however, that there is a much lower frequency of germline HNPCC mutations among the great majority of sporadic colon cancer patients, who present at over 45 years of age. The estimate that 15% of all CRCs result from HNPCC is probably much too high. It is unlikely that new or low penetrance HNPCC mutations contribute significantly to the risk of colorectal cancer in the general population. If so, mass population screening for germline defects at HNPCC loci20 may be of relatively little value until technological advances have made the task of mutation detection very much easier.
